The US Food and Drug Administration (FDA) has permitted Pear Therapeutics to market the mobile medical application, Reset, to aid substance use disorder (SUD) treatment.

The Reset mobile medical application system is indicated for alcohol, cocaine, marijuana and stimulant SUDs, but not for treatment of opioid dependence.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Designed to be used in conjunction with outpatient therapy and a contingency management system commonly used to treat SUDs, the Reset features a patient application and clinician dashboard.

The device provides cognitive behavioural therapy to patients by teaching skills that help to enhance abstinence from substance abuse and elevate retention of outpatient therapy programmes.

FDA Centre for Devices and Radiological Health Neurological and Physical Medicine Devices division director Carlos Peña said: “This is an example of how innovative digital technologies can help provide patients access to additional tools during their treatment.

"Results indicated a statistically significant increase of 40.3% in adherence to abstinence for the patients who used Reset, compared to 17.6% in the standard treatment group."

“More therapy tools mean a greater potential to help improve outcomes, including abstinence, for patients with substance use disorder.”

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The FDA permit is based on the data obtained during a multi-centre, unblinded 12-week clinical trial performed in 399 subjects who received standard treatment in combination with the desktop-based version of Reset or standard treatment alone.

Results indicated a statistically significant increase of 40.3% in adherence to abstinence for the patients who used Reset, compared to 17.6% in the standard treatment group.

The Reset device is indicated as a prescription-only adjunct treatment for SUD patients who are not currently on opioid replacement therapy, and for people who do not solely abuse alcohol or opioids.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Awarded for Innovation in Remote Hearing Diagnostics , hearX’s Self Test Kit (STK) delivers clinically validated audiometry via smart devices, enabling remote, scalable hearing assessments in homes, clinics and retail. Learn how hearX is redefining hearing care delivery and reducing costs for providers globally.

Discover the Impact